Nexam Chemical

Nexam Chemical

Sälj aktien Köp aktien Handla aktien direkt på nordnet

« Tillbaka

Nexam Chemical - Solid Q2, profitability within reach

14 juli 2026

  • Sales SEK 60m (+9% vs. ABGSCe), first EBIT-positive quarter
  • We continue to forecast full-year profitability from '27e
  • Recycling +76% y-o-y, '26 doubling ambition intact

Q2 results

Nexam reported record quarterly sales of SEK 60m (+11% y-o-y, +9% vs. ABGSCe), after a weaker Q1. Recycling was again the highlight at SEK 10.2m (+76% y-o-y), passing SEK 10m in a quarter for the first time, while Performance Chemicals rose 16% and Masterbatch 7%. Lightweighting improved vs. a weak Q1, although management notes quarterly fluctuations remain, and High Temperature is still held back by NA destocking. EBIT came in positive at SEK 0.1m (ABGSCe -1.8m). The profitability came from operating leverage: +11% sales growth on a broadly flat cost base.

Estimate changes

We only partially extrapolate the strong Q2 into the rest of '26e, as quarterly sales remain volatile and management flags Q3 as the seasonally weaker holiday quarter. We raise '26e-'28e sales by 1-2% and total EBIT by SEK 3m after the report, and continue to expect Nexam to reach positive full-year EBIT in '27e.

Recycling becoming an earnings driver

At ~17% of sales and growing 76%, Recycling is transitioning from option value to earnings driver, supported by the virgin-price surge (PET/PE +40% in June per management) that shifts recycling from sustainability choice to cost necessity, consistent with the thesis in our Q1 note. The concentration point cuts both ways: growth so far is driven by a few large accounts ramping up, and the pipeline's conversion to serial production is the key swing factor for the doubling ambition in 2026. The share has returned +39% L3M (vs. peers +5%, OMXSALLS +3%) and is trading at 1.7x-1.3x '26e-'28e EV/Sales vs. the peer median of 1.3x-0.7x.

Senaste artiklar från alla bolag

Datum Titel Bolag Typ
2026-08-25 Isofol Medical - Maximising the dose before Phase 2 Isofol Medical Analys
2026-08-24 Skolon - Broad-based growth continues Skolon Analys
2026-08-24 Gentoo Media - FCF generation remains top priority Gentoo Media Analys
2026-08-24 Impact Coatings - Backlog to carry H2e Impact Coat.. Analys
2026-08-24 I-tech - Beyond a single molecule I-tech Analys
2026-08-23 Catella - Signs of improvement, but delivery stil... Catella Analys
2026-08-23 Ogunsen - Some signs of stabilisation Ogunsen Analys
2026-08-21 Clavister - Strong quarter strengthens the outlook Clavister Analys
2026-08-21 Generic - Investing while growing Generic Analys
2026-08-21 Impact Coatings - A quarter driven by Coating Ser... Impact Coat.. Analys
2026-08-21 Skolon - Sweden profitability gains continue Skolon Analys
2026-08-21 I-tech - Strongest quarter on record I-tech Analys
2026-08-20 Tempest Security - Patrols below plan Tempest Sec.. Analys
2026-08-20 Tempest Security - Progress made but expectations... Tempest Sec.. Analys
2026-08-20 Ascelia Pharma - Still alive: Fighting to reverse... Ascelia Pharma Analys
2026-08-20 Clavister - Defence drives record quarter Clavister Analys
2026-08-20 Catella - Q2 softer than expected, but underlying... Catella Analys
2026-08-20 Generic - Volumes continue to grow Generic Analys
2026-08-19 SinterCast - Past the trough, but recovery pace u... SinterCast Analys
2026-08-19 Xplora Technologies - EBITDA -13% on soft senior ... Xplora Tech.. Analys